Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 599626

Drug Profile

BMS 599626

Alternative Names: AC480; BMS599626

Latest Information Update: 18 Jun 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Ambit Biosciences Corporation; Bristol-Myers Squibb
  • Class Antineoplastics; Heterocyclic bicyclo compounds; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists; ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Glioma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 23 Jul 2015 Discontinued - Phase-I for Breast cancer, Glioma, Non-small cell lung cancer and Solid tumours (Combination therapy) in USA after October 2013 (IV)
  • 22 Jun 2015 Ambit Biosciences withdraws phase-I trial in Solid tumours in USA prior to enrolment (Combination therapy) (NCT01245543)
  • 10 Nov 2014 Ambit Biosciences Corporation has been acquired by Daiichi Sankyo Company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top